European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026: Conference Highlights

ESCMID Global is the annual congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (formerly ECCMID).

ESCMID Global 2026 took place in took place in Munich, Germany, between April 17 and 21.

GlobalData attended industry-sponsored symposia as well as scientific sessions where key therapies were featured, the contents of which were analyzed to create this ESCMID Global 2026 Highlights report.

Scope

Indications, therapies, and companies discussed -

Respiratory Syncytial Virus (RSV)

• Zelicapavir - Enanta Pharmaceuticals
• Nirsevimab - AstraZeneca

Influenza

• mRNA-1010 - Moderna

COVID-19

• Secutrelvir - Shionogi & Co

Herpes Simplex Virus (HSV)

• Pritelivir - AiCuris
• Adibelivir (IM-250) - Innovative Molecules

Chikungunya Virus (CHIKV)

• EVT894 - Evotec

Hepatitis B (HBV)

• TherVacB - Helmholtz-Zentrum fur Umweltforschung

Fungal Infections

• Olorofim - F2G
• SCY-247 - Scynexis

Reasons to Buy

This powerpoint-based deliverable provides analysis on key presentations from the conference, and what they mean for your strategy, covering disease areas such as RSV, HSV, HBV, fungal infections, and more.

Inside the report you'll find -

• Emerging trends in prophylactic or therapeutic strategies for the management of viral and fungal infections
• Insights into the disease areas and key sponsors that took precedence at the conference
• Key takeaways from headline sessions and late-breaking data
• Clinical and commercial implications of notable presentations